Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Steris

STE Healthcare Unknown Updated August 01, 2026
$228.46
52W $195.14 – $269.44
61/100
$22.26B
28.7
0.92
AI Committee Verdict
Buy
Conviction: Contested · 57% agreement · 7 analysts
+10.6%
-8.0%
1.33:1
Contested

Is STE Bullish or Bearish?

Bullish. Innellis AI committee rates Steris (STE) Buy with a composite score of 61/100 , based on 7 analysts with 57% agreement. Last updated August 01, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +14.06 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -5.94 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull & Bear Case

Bull Case
  • EPS growing 27.9% YoY — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Low leverage (debt-to-equity 0.27) -- balance sheet can absorb a shock — Risk
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • P/E of 28.5 is moderate-to-rich — Value
  • 2 consecutive earnings misses -- execution concerns — Growth
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 01, 2026
Overall Committee Score
61/100
Agreement
57%
Analysts
7
Conviction
Contested
Sector Rank
Top 16%
of 93 Healthcare peers
Value Analyst neutral
55 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 28.5 is moderate-to-rich
Growth Analyst neutral
58 / 100 · High confidence
Moderate growth -- present but not remarkable
+ EPS growing 27.9% YoY
− 2 consecutive earnings misses -- execution concerns
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst bullish
80 / 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.27) -- balance sheet can absorb a shock
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
61 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2535.03)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 59.1 to 60.9.

Analyst-level changes:
  • Macro Analyst: stance neutral->bullish; score 58->70 (+12).
  • Portfolio Manager: +2 bearish signal(s).

Comparing 2026-07-31 to 2026-08-01 (1 day apart).

Technical Analysis

RSI (14)
63.1
Neutral
MACD Histogram
1.876
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Lh Ll
Support
$210.23
Resistance
$252.76
Bollinger %B
0.85
Inside Bands
Price vs Moving Averages
EMA 9
$224.13 Above
EMA 21
$219.01 Above
EMA 50
$216.37 Above
EMA 200
$226.69 Above

Fundamental Analysis

Valuation
73
Growth
57
Profitability
0
Financial Health
100
Cash Flow
37
Valuation
P/E Ratio 28.7×
P/B Ratio 3.12×
PEG Ratio 1.04
Dividend Yield 0.01%
52W High $269.44
52W Low $195.14
Quality & Growth
ROE 10.9%
ROA 7.3%
Gross Margin 44.2%
Operating Margin 18.6%
Revenue Growth YoY
Debt / Equity 0.29
AI Fundamental Assessment
P/E ratio of 28.7 (moderate relative to a 15-40x range); Price-to-book of 3.1x; PEG ratio of 1.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.1%; Net margin of 0.1%; Gross margin of 0.4%; Current ratio of 2.09 (healthy short-term liquidity); Debt-to-equity of 0.29; Free cash flow margin of 0.7% (thin cash generation); Free cash flow per share is positive (9.92); Most recent quarter missed estimates by 1.6%; 2 consecutive earnings misses; EPS growth accelerating (+2.4% -> +11.9% QoQ); Analyst estimates rising over recent quarters
Get the Full STE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore STE Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime